相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade
T. Gambichler et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma
S. Ugurel et al.
ANNALS OF ONCOLOGY (2020)
Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients
Mehdi R. Pirozyan et al.
FRONTIERS IN IMMUNOLOGY (2020)
In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
Haris Babacic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
Anne Froehlich et al.
EBIOMEDICINE (2020)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles
Moira Graves et al.
FRONTIERS IN MEDICINE (2019)
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
Lorena Incorvaia et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Douglas B. Johnson et al.
JCI INSIGHT (2018)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Shuguang Tan et al.
NATURE COMMUNICATIONS (2017)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Late-Breaking Abstracts Abstracts
[Anonymous]
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
Alena Gros et al.
NATURE MEDICINE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani et al.
CELL RESEARCH (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wenshi Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Patrice Hemon et al.
JOURNAL OF IMMUNOLOGY (2011)
LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis
Creg J. Workman et al.
JOURNAL OF IMMUNOLOGY (2009)
Metalloproteases regulate T-cell proliferation and effector function via LAG-3
Nianyu Li et al.
EMBO JOURNAL (2007)
Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation
Harmjan Kuipers et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity
C Casati et al.
CANCER RESEARCH (2006)
Alternative splice variants of the human PD-1 gene
C Nielsen et al.
CELLULAR IMMUNOLOGY (2005)
LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors
S Buisson et al.
IMMUNOLOGY (2005)
Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223)
NY Li et al.
JOURNAL OF IMMUNOLOGY (2004)
分享论文
